Related Experiment Video
Updated: May 26, 2026

Three-Dimensional Collagen Matrix Scaffold Implantation as a Liver Regeneration Strategy
Published on: June 29, 2021
Liver Anti-Fibrosis Therapy with Mesenchymal Stem Cells Secreting Hepatocyte Growth Factor
Hidefumi Ishikawa1, Jun-Ichiro Jo, Yasuhiko Tabata
1a Department of Biomaterials , Institute for Frontier Medical Sciences, Kyoto University , 53 Kawara-cho Shogoin , Sakyo-ku , Kyoto , 606-8507 , Japan.
Abstract:
The objective of this study is to investigate the anti-fibrotic effect of combined mesencymal stem cells (MSCs) and gene therapy on liver fibrosis. When transfected by the complex with a plasmid DNA of hepatocyte growth factor (HGF) and the spermine-introduced pullulan of gene carrier, MSCs secreted HGF protein over 1 week. The HGF secreted from transfected MSC had the biological activity to promote the albumin production of hepatocytes. After intravenous injection, the HGF-secreting MSCs (HGF-MSC) accumulated in the liver. The injection of HGF-MSC decreased the fibrosis area in a rat model of liver fibrosis to a significantly great extent compared with that of original MSC. In the in vitro experiment, the higher number of HGF-transfected MSCs was migrated by stromal cell-derived factor (SDF)-1α more strongly than the original MSC. Considering the promotion of SDF-1α secretion in the liver fibrosis, it is possible that, when transplanted, genetically-engineered MSCs are accumulated in the liver due to their higher response to SDF-1α. It is concluded that the intravenous injection of genetically-engineered MSCs is a promising therapy for liver fibrosis.
Related Concept Videos
Liver Regeneration
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are large...
Healing I: Introduction
Cirrhosis II: Pathophysiology
Mesenchymal Stem Cells

